Kasra Shakeri-Nejad Selected Research

Kasra Shakeri-Nejad Research Topics

2	Multiple Sclerosis 06/2023 - 01/2022
1	Nasal Polyps (Nasal Polyp) 02/2024
1	Asthma (Bronchial Asthma) 02/2024
1	Chronic Urticaria 02/2024
1	Rhinosinusitis 02/2024
1	Fascioliasis 10/2023
1	Disease Progression 06/2023
1	Severe Acute Respiratory Syndrome 06/2023
1	COVID-19 06/2023
1	Atrioventricular Block 01/2020
1	Human Influenza (Influenza) 11/2017
1	Alzheimer Disease (Alzheimer's Disease) 03/2015
1	Schizophrenia (Dementia Praecox) 03/2015
1	Cognitive Dysfunction 03/2015
1	Nervous System Diseases (Neurological Disorders) 03/2015
1	Hypertension (High Blood Pressure) 02/2014
1	Liver Diseases (Liver Disease) 12/2008
1	Bacterial Infections (Bacterial Infection) 04/2006

3	siponimodIBA 06/2023 - 11/2017
2	Sphingosine-1-Phosphate ReceptorsIBA 06/2023 - 01/2022
1	Monoclonal AntibodiesIBA 02/2024
1	Omalizumab (Xolair)FDA Link 02/2024
1	anti-IgE antibodiesIBA 02/2024
1	TriclabendazoleIBA 10/2023
1	Fingolimod Hydrochloride (FTY720)FDA Link 06/2023
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 01/2022
1	AntigensIBA 11/2017
1	Immunoglobulins (Immunoglobulin)IBA 11/2017
1	VaccinesIBA 11/2017
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 11/2017
1	3- (6- p- tolylpyridin- 3- yloxy)- 1- azabicyclo(2.2.2)octaneIBA 03/2015
1	Cholinergic ReceptorsIBA 03/2015
1	isobutyric acid 2- (2- ((3- (4,7- dimethoxy- 1H- benzoimidazol- 2- yl)propyl)methylamino)ethyl)- 5- phenylbicyclo(2.2.2)oct- 5- en- 2- yl esterIBA 02/2014
1	Dabigatran FDA Link 12/2008
1	QuinolonesIBA 04/2006
1	MacrolidesIBA 04/2006
1	AzolesIBA 04/2006
1	Anti-Infective Agents (Microbicides)IBA 04/2006
1	KetolidesIBA 04/2006

1	Critical Care (Surgical Intensive Care) 06/2023
1	Intramuscular Injections 11/2017
1	Therapeutics 04/2006